<DOC>
	<DOCNO>NCT00006485</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine flavopiridol irinotecan treating patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Flavopiridol Irinotecan Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose flavopiridol combine irinotecan patient advance solid tumor . - Determine clinical pharmacokinetics regimen , well plasma level active metabolite SN-38 metabolic product SN-38 glucuronide patient . - Determine , preliminary manner , therapeutic activity regimen patient . - Determine role p21 relative treatment response apoptosis patient treat regimen . OUTLINE : This dose-escalation , open-label , non-randomized study flavopiridol . Patients receive irinotecan IV 30 minute follow 7 hour later flavopiridol IV 1 hour day 1 , 8 , 15 , 22 . Treatment continue every 6 week minimum 2 course absence disease progression unacceptable toxicity . During first week second course , patient receive flavopiridol alone day 1 irinotecan alone day 2 . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient initial cohort experience dose limit toxicity first course treatment . An additional 10 patient treated MTD . PROJECTED ACCRUAL : A total 44-50 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally advanced metastatic solid tumor refractory standard therapy standard therapy exist Eligible treatment maximum tolerate dose disease accessible tissue biopsy TruCut , CT guidance , endoscopy Pleural effusion abdominal ascites constitute adequate tissue biopsy No known CNS metastasis primary CNS tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Total neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No cardiac arrhythmia , congestive heart failure , myocardial infarction within past 6 month Other : Not pregnant nursing ( least 2 month study ) Negative pregnancy test Fertile patient must use effective contraception least 2 month study No concurrent serious uncontrolled infection HIV negative No medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior irinotecan allow Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : Recovered prior therapy No concurrent investigational medication No concurrent vitamin ( except single multivitamin tablet ) , antioxidant , herbal preparation supplement No concurrent subcutaneous heparin heparinoids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>